TY - JOUR
T1 - Rabbit antithymocyte globulin (Thymoglobulin®)
T2 - 25 Years and new frontiers in solid organ transplantation and haematology
AU - Gaber, A. Osama
AU - Monaco, Anthony P.
AU - Russell, James A.
AU - Lebranchu, Yvon
AU - Mohty, Mohamad
N1 - Funding Information:
The authors would like to thank Dr Kathleen Romaszko, of MedLogix Communications, for editorial support. Dr Romaszko assisted the authors with searching the medical literature, procuring references and preparing the manuscript. The authors reviewed and approved all supporting references cited and provided critical revision of this manuscript. This paper was supported by Genzyme Corporation; no honoraria were provided to the authors for their participation. Dr Gaber has served on an advisory board for Genzyme; Dr Russell has received honoraria and has a study grant pending from Gen-zyme; and Dr Mohty has acted as a consultant for Genzyme, Amgen and Janssen, received honoraria from Genzyme, Amgen, Janssen, Celgene and Pierre Fabre, and received grants from Genzyme and Pierre Fabre.
Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2010
Y1 - 2010
N2 - The more than 25 years of clinical experience with rabbit antithymocyte globulin (rATG), specifically Thymoglobulin®, has transformed immunosuppression in solid organ transplantation and haematology. The utility of rATG has evolved from the treatment of allograft rejection and graft-versus-host disease to the prevention of various complications that limit the success of solid organ and stem cell transplantation. Today, rATG is being successfully incorporated into novel therapeutic regimens that seek to reduce overall toxicity and improve long-term outcomes. Clinical trials have demonstrated the efficacy and safety of rATG in recipients of various types of solid organ allografts, recipients of allogeneic stem cell transplants who are conditioned with both conventional and nonconventional regimens, and patients with aplastic anaemia. Over time, clinicians have learnt how to better balance the benefits and risks associated with rATG. Advances in the understanding of the multifaceted mechanism of action will guide research into new therapeutic areas and future applications.
AB - The more than 25 years of clinical experience with rabbit antithymocyte globulin (rATG), specifically Thymoglobulin®, has transformed immunosuppression in solid organ transplantation and haematology. The utility of rATG has evolved from the treatment of allograft rejection and graft-versus-host disease to the prevention of various complications that limit the success of solid organ and stem cell transplantation. Today, rATG is being successfully incorporated into novel therapeutic regimens that seek to reduce overall toxicity and improve long-term outcomes. Clinical trials have demonstrated the efficacy and safety of rATG in recipients of various types of solid organ allografts, recipients of allogeneic stem cell transplants who are conditioned with both conventional and nonconventional regimens, and patients with aplastic anaemia. Over time, clinicians have learnt how to better balance the benefits and risks associated with rATG. Advances in the understanding of the multifaceted mechanism of action will guide research into new therapeutic areas and future applications.
UR - http://www.scopus.com/inward/record.url?scp=77951052617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951052617&partnerID=8YFLogxK
U2 - 10.2165/11315940-000000000-00000
DO - 10.2165/11315940-000000000-00000
M3 - Review article
C2 - 20394456
AN - SCOPUS:77951052617
SN - 0012-6667
VL - 70
SP - 691
EP - 732
JO - Drugs
JF - Drugs
IS - 6
ER -